Impact of Ketogenic Diet on Tumor Microenvironment in Patients With Breast Cancer
Part of paid clinical trials in San Antonio, Texas.
- Sponsor
- The University of Texas Health Science Center at San Antonio
- Study ID
- NCT07574671
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Ketogenic diet — OTHERThe ketogenic diet will be comprised of a low carbohydrate, high fat diet.
Study Details
This study is testing the effects of a ketogenic diet on patients with early stage breast cancer. Participants will keep to a ketogenic diet for 3 weeks prior to surgery.
Key Dates
- Start date
- Apr 2, 2026
- Status verified
- Apr 2026
- Primary completion
- Apr 30, 2027
- Completion
- Apr 30, 2028
Study Design
- Enrollment
- 12 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- BASIC_SCIENCE
Arms
- Experimental: Ketogenic Diet Treatment armPatients with early-stage breast cancer will adhere to a ketogenic diet for 3 weeks prior to surgery.
Primary Outcome Measure
Change in tumor immune microenvironment [ Time Frame: Baseline to 3 weeks ]
Central Contacts
- Joseph Terrones210-450-5098
- Kayla Chamberlin, RN, BSN210-450-5964
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mays Cancer Center, UT Health San Antonio | San Antonio | Texas | 78229 | Kayla Chamberlin, RN, BSN |
Find similar trials in San Antonio, TX
By condition
By specialty
By research site
Related Studies
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPHASE2 · Recruiting · QuantumLeap Healthcare Collaborative · Birmingham, Alabama
- MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression ProfilesRecruiting · Agendia · Birmingham, Alabama
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast CancerPHASE3 · Recruiting · Canadian Cancer Trials Group · Fairbanks, Alaska